Metro International Biotech, LLC

Cardurion Pharmaceuticals, LLC

Johnson Matthey Public Limited Company

Mateusz Pitak

Bruce G Szczepankiewicz

Jonathan N Kremsky

Suzanne Buttar

Haojuan Wei

Martin Bates

Joseph Harris

Karsten Koppetsch

Adam Ross Patterson

Kuangchu Dai

Ioana Sovago

Carin Seechurn

Peng Zhou

Jun Xu

Rachel Kahan

The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one.

Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

A compound of formula (I) wherein M is Pd(II) or Ni(II); X is a halide; Rand Rare independently organic groups having 1-20 carbon atoms, or Rand Rare linked to form a ring structure with the phosphorus atom; Ris an organic group having 1-20 carbon atoms; provided that R, R, Rare not each phenyl.

Transition metal dimer complex as a catalyst

The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.

The present disclosure relates to crystalline solids comprising a compound of Formula (I), wherein R is n-propyl, and methods of making compounds of Formula (I) wherein R is C1-C4 alkyl or C2-C4 alkenyl. The present disclosure also relates to crystalline solids comprising a compound of Formula (II), The present disclosure further relates to methods of preparing the crystalline solids, and pharmaceutical preparations of the crystalline solids, and use of such pharmaceutical preparations in treatment of diseases and conditions.

Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Growing community of inventors

Cambridge, United Kingdom

Mateusz Pitak